Skip to main content

FTC orders Illumina to divest cancer test maker Grail on competition grounds

Illumina acquired Grail in 2021 despite concerns from regulators in the U.S. and Europe. The company will appeal the FTC decision.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.